1 Market Overview of CDK4/6 Inhibitors for Breast Cancer 1.1 CDK4/6 Inhibitors for Breast Cancer Market Overview 1.1.1 CDK4/6 Inhibitors for Breast Cancer Product Scope 1.1.2 CDK4/6 Inhibitors for Breast Cancer Market Status and Outlook 1.2 Global CDK4/6 Inhibitors for Breast Cancer Market Size Overview by Region 2016 VS 2021VS 2027 1.3 Global CDK4/6 Inhibitors for Breast Cancer Market Size by Region (2016-2027) 1.4 Global CDK4/6 Inhibitors for Breast Cancer Historic Market Size by Region (2016-2021) 1.5 Global CDK4/6 Inhibitors for Breast Cancer Market Size Forecast by Region (2022-2027) 1.6 Key Regions, CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) 1.6.1 North America CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) 1.6.2 Europe CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) 1.6.3 Asia-Pacific CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) 1.6.4 Latin America CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) 1.6.5 Middle East & Africa CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) 2 CDK4/6 Inhibitors for Breast Cancer Market Overview by Type 2.1 Global CDK4/6 Inhibitors for Breast Cancer Market Size by Type: 2016 VS 2021 VS 2027 2.2 Global CDK4/6 Inhibitors for Breast Cancer Historic Market Size by Type (2016-2021) 2.3 Global CDK4/6 Inhibitors for Breast Cancer Forecasted Market Size by Type (2022-2027) 2.4 Palbociclib 2.5 Ribociclib 2.6 Abemaciclib 3 CDK4/6 Inhibitors for Breast Cancer Market Overview by Application 3.1 Global CDK4/6 Inhibitors for Breast Cancer Market Size by Application: 2016 VS 2021 VS 2027 3.2 Global CDK4/6 Inhibitors for Breast Cancer Historic Market Size by Application (2016-2021) 3.3 Global CDK4/6 Inhibitors for Breast Cancer Forecasted Market Size by Application (2022-2027) 3.4 Hospital 3.5 Clinic 3.6 Drug Center 3.7 Other 4 CDK4/6 Inhibitors for Breast Cancer Competition Analysis by Players 4.1 Global CDK4/6 Inhibitors for Breast Cancer Market Size by Players (2016-2021) 4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in CDK4/6 Inhibitors for Breast Cancer as of 2020) 4.3 Date of Key Players Enter into CDK4/6 Inhibitors for Breast Cancer Market 4.4 Global Top Players CDK4/6 Inhibitors for Breast Cancer Headquarters and Area Served 4.5 Key Players CDK4/6 Inhibitors for Breast Cancer Product Solution and Service 4.6 Competitive Status 4.6.1 CDK4/6 Inhibitors for Breast Cancer Market Concentration Rate 4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data 5.1 Pfizer 5.1.1 Pfizer Profile 5.1.2 Pfizer Main Business 5.1.3 Pfizer CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions 5.1.4 Pfizer CDK4/6 Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.1.5 Pfizer Recent Developments 5.2 Beacon Pharmaceuticals 5.2.1 Beacon Pharmaceuticals Profile 5.2.2 Beacon Pharmaceuticals Main Business 5.2.3 Beacon Pharmaceuticals CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions 5.2.4 Beacon Pharmaceuticals CDK4/6 Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.2.5 Beacon Pharmaceuticals Recent Developments 5.3 Incepta Pharmaceuticals 5.5.1 Incepta Pharmaceuticals Profile 5.3.2 Incepta Pharmaceuticals Main Business 5.3.3 Incepta Pharmaceuticals CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions 5.3.4 Incepta Pharmaceuticals CDK4/6 Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.3.5 Pharmaceuticals Recent Developments 5.4 Pharmaceuticals 5.4.1 Pharmaceuticals Profile 5.4.2 Pharmaceuticals Main Business 5.4.3 Pharmaceuticals CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions 5.4.4 Pharmaceuticals CDK4/6 Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.4.5 Pharmaceuticals Recent Developments 5.5 Bluepharma 5.5.1 Bluepharma Profile 5.5.2 Bluepharma Main Business 5.5.3 Bluepharma CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions 5.5.4 Bluepharma CDK4/6 Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.5.5 Bluepharma Recent Developments 5.6 NANO DARU 5.6.1 NANO DARU Profile 5.6.2 NANO DARU Main Business 5.6.3 NANO DARU CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions 5.6.4 NANO DARU CDK4/6 Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.6.5 NANO DARU Recent Developments 5.7 Eli Lilly 5.7.1 Eli Lilly Profile 5.7.2 Eli Lilly Main Business 5.7.3 Eli Lilly CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions 5.7.4 Eli Lilly CDK4/6 Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.7.5 Eli Lilly Recent Developments 5.8 Novartis 5.8.1 Novartis Profile 5.8.2 Novartis Main Business 5.8.3 Novartis CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions 5.8.4 Novartis CDK4/6 Inhibitors for Breast Cancer Revenue (US$ Million) & (2016-2021) 5.8.5 Novartis Recent Developments 6 North America 6.1 North America CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2016-2027) 6.2 United States 6.3 Canada 7 Europe 7.1 Europe CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2016-2027) 7.2 Germany 7.3 France 7.4 U.K. 7.5 Italy 7.6 Russia 7.7 Nordic 7.8 Rest of Europe 8 Asia-Pacific 8.1 Asia-Pacific CDK4/6 Inhibitors for Breast Cancer Market Size by Region (2016-2027) 8.2 China 8.3 Japan 8.4 South Korea 8.5 Southeast Asia 8.6 India 8.7 Australia 8.8 Rest of Asia-Pacific 9 Latin America 9.1 Latin America CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2016-2027) 9.2 Mexico 9.3 Brazil 9.4 Rest of Latin America 10 Middle East & Africa 10.1 Middle East & Africa CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2016-2027) 10.2 Turkey 10.3 Saudi Arabia 10.4 UAE 10.5 Rest of Middle East & Africa 11 CDK4/6 Inhibitors for Breast Cancer Market Dynamics 11.1 CDK4/6 Inhibitors for Breast Cancer Industry Trends 11.2 CDK4/6 Inhibitors for Breast Cancer Market Drivers 11.3 CDK4/6 Inhibitors for Breast Cancer Market Challenges 11.4 CDK4/6 Inhibitors for Breast Cancer Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer 13.4 Author List

List of Tables Table 1. Global Market CDK4/6 Inhibitors for Breast Cancer Market Size (US$ Million) Comparison by Region 2016 VS 2021 VS 2027 Table 2. Global CDK4/6 Inhibitors for Breast Cancer Market Size by Region (2016-2021) & (US$ Million) Table 3. Global CDK4/6 Inhibitors for Breast Cancer Market Size Share by Region (2016-2021) Table 4. Global CDK4/6 Inhibitors for Breast Cancer Forecasted Market Size by Region (2022-2027) & (US$ Million) Table 5. Global CDK4/6 Inhibitors for Breast Cancer Forecasted Market Size Share by Region (2022-2027) Table 6. Global CDK4/6 Inhibitors for Breast Cancer Market Size (US$ Million) by Type: 2016 VS 2021 VS 2027 Table 7. Global CDK4/6 Inhibitors for Breast Cancer Market Size by Type (2016-2021) & (US$ Million) Table 8. Global CDK4/6 Inhibitors for Breast Cancer Revenue Market Share by Type (2016-2021) Table 9. Global CDK4/6 Inhibitors for Breast Cancer Forecasted Market Size by Type (2022-2027) & (US$ Million) Table 10. Global CDK4/6 Inhibitors for Breast Cancer Revenue Market Share by Type (2022-2027) Table 11. Global CDK4/6 Inhibitors for Breast Cancer Market Size (US$ Million) by Application: 2016 VS 2021 VS 2027 Table 12. Global CDK4/6 Inhibitors for Breast Cancer Market Size by Application (2016-2021) & (US$ Million) Table 13. Global CDK4/6 Inhibitors for Breast Cancer Revenue Market Share by Application (2016-2021) Table 14. Global CDK4/6 Inhibitors for Breast Cancer Forecasted Market Size by Application (2022-2027) & (US$ Million) Table 15. Global CDK4/6 Inhibitors for Breast Cancer Revenue Market Share by Application (2022-2027) Table 16. Global CDK4/6 Inhibitors for Breast Cancer Revenue (US$ Million) by Players (2016-2021) Table 17. Global CDK4/6 Inhibitors for Breast Cancer Revenue Market Share by Players (2016-2021) Table 18. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in CDK4/6 Inhibitors for Breast Cancer as of 2020) Table 19. Date of Key Manufacturers Enter into CDK4/6 Inhibitors for Breast Cancer Market Table 20. Global CDK4/6 Inhibitors for Breast Cancer Top Players Headquarters and Area Served Table 21. CDK4/6 Inhibitors for Breast Cancer Product Solution and Service Table 22. Global CDK4/6 Inhibitors for Breast Cancer Players Market Concentration Ratio (CR5 and HHI) Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Pfizer Basic Information List Table 25. Pfizer Description and Business Overview Table 26. Pfizer CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions Table 27. Revenue (US$ Million) in CDK4/6 Inhibitors for Breast Cancer Business of Pfizer (2016-2021) Table 28. Pfizer Recent Developments Table 29. Beacon Pharmaceuticals Basic Information List Table 30. Beacon Pharmaceuticals Description and Business Overview Table 31. Beacon Pharmaceuticals CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions Table 32. Revenue (US$ Million) in CDK4/6 Inhibitors for Breast Cancer Business of Beacon Pharmaceuticals (2016-2021) Table 33. Beacon Pharmaceuticals Recent Developments Table 34. Incepta Pharmaceuticals Basic Information List Table 35. Incepta Pharmaceuticals Description and Business Overview Table 36. Incepta Pharmaceuticals CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions Table 37. Revenue (US$ Million) in CDK4/6 Inhibitors for Breast Cancer Business of Incepta Pharmaceuticals (2016-2021) Table 38. Incepta Pharmaceuticals Recent Developments Table 39. Pharmaceuticals Basic Information List Table 40. Pharmaceuticals Description and Business Overview Table 41. Pharmaceuticals CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions Table 42. Revenue (US$ Million) in CDK4/6 Inhibitors for Breast Cancer Business of Pharmaceuticals (2016-2021) Table 43. Pharmaceuticals Recent Developments Table 44. Bluepharma Basic Information List Table 45. Bluepharma Description and Business Overview Table 46. Bluepharma CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions Table 47. Revenue (US$ Million) in CDK4/6 Inhibitors for Breast Cancer Business of Bluepharma (2016-2021) Table 48. Bluepharma Recent Developments Table 49. NANO DARU Basic Information List Table 50. NANO DARU Description and Business Overview Table 51. NANO DARU CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions Table 52. Revenue (US$ Million) in CDK4/6 Inhibitors for Breast Cancer Business of NANO DARU (2016-2021) Table 53. NANO DARU Recent Developments Table 54. Eli Lilly Basic Information List Table 55. Eli Lilly Description and Business Overview Table 56. Eli Lilly CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions Table 57. Revenue (US$ Million) in CDK4/6 Inhibitors for Breast Cancer Business of Eli Lilly (2016-2021) Table 58. Eli Lilly Recent Developments Table 59. Novartis Basic Information List Table 60. Novartis Description and Business Overview Table 61. Novartis CDK4/6 Inhibitors for Breast Cancer Products, Services and Solutions Table 62. Revenue (US$ Million) in CDK4/6 Inhibitors for Breast Cancer Business of Novartis (2016-2021) Table 63. Novartis Recent Developments Table 64. North America CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 65. North America CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 66. Europe CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 67. Europe CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 68. Asia-Pacific CDK4/6 Inhibitors for Breast Cancer Market Size by Region (2016-2021) & (US$ Million) Table 69. Asia-Pacific CDK4/6 Inhibitors for Breast Cancer Market Size by Region (2022-2027) & (US$ Million) Table 70. Asia-Pacific CDK4/6 Inhibitors for Breast Cancer Market Share by Region (2016-2021) Table 71. Asia-Pacific CDK4/6 Inhibitors for Breast Cancer Market Share by Region (2022-2027) Table 72. Latin America CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2016-2021) & (US$ Million) Table 73. Latin America CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 74. Middle East & Africa CDK4/6 Inhibitors for Breast Cancer Market Size by Players (2016-2021) & (US$ Million) Table 75. Middle East & Africa CDK4/6 Inhibitors for Breast Cancer Market Size by Country (2022-2027) & (US$ Million) Table 76. CDK4/6 Inhibitors for Breast Cancer Market Trends Table 77. CDK4/6 Inhibitors for Breast Cancer Market Drivers Table 78. CDK4/6 Inhibitors for Breast Cancer Market Challenges Table 79. CDK4/6 Inhibitors for Breast Cancer Market Restraints Table 80. Research Programs/Design for This Report Table 81. Key Data Information from Secondary Sources Table 82. Key Data Information from Primary Sources List of Figures Figure 1. Global CDK4/6 Inhibitors for Breast Cancer Market Size Year-over-Year 2016-2027 & (US$ Million) Figure 2. Global CDK4/6 Inhibitors for Breast Cancer Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 3. Global CDK4/6 Inhibitors for Breast Cancer Market Share by Regions: 2021 VS 2027 Figure 4. Global CDK4/6 Inhibitors for Breast Cancer Forecasted Market Size Share by Region (2022-2027) Figure 5. North America CDK4/6 Inhibitors for Breast Cancer Market Size (US$ Million) Growth Rate (2016-2027) Figure 6. Europe CDK4/6 Inhibitors for Breast Cancer Market Size (US$ Million) and Growth Rate (2016-2027) Figure 7. Asia-Pacific CDK4/6 Inhibitors for Breast Cancer Market Size (US$ Million) and Growth Rate (2016-2027) Figure 8. Latin America CDK4/6 Inhibitors for Breast Cancer Market Size (US$ Million) and Growth Rate (2016-2027) Figure 9. Middle East & Africa CDK4/6 Inhibitors for Breast Cancer Market Size (US$ Million) and Growth Rate (2016-2027) Figure 10. Global CDK4/6 Inhibitors for Breast Cancer Market Size Share by Type in 2021 & 2027 Figure 11. Palbociclib Market Size (US$ Million) YoY Growth (2016-2027) Figure 12. Ribociclib Market Size (US$ Million) YoY Growth (2016-2027) Figure 13. Abemaciclib Market Size (US$ Million) YoY Growth (2016-2027) Figure 14. Global CDK4/6 Inhibitors for Breast Cancer Market Size Share by Application in 2021 & 2027 Figure 15. Hospital Market Size (US$ Million) YoY Growth (2016-2027) Figure 16. Clinic Market Size (US$ Million) YoY Growth (2016-2027) Figure 17. Drug Center Market Size (US$ Million) YoY Growth (2016-2027) Figure 18. Other Market Size (US$ Million) YoY Growth (2016-2027) Figure 19. CDK4/6 Inhibitors for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020 Figure 20. Global Top 5 and Top 10 Players CDK4/6 Inhibitors for Breast Cancer Market Share in 2020 Figure 21. North America CDK4/6 Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 22. United States CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 23. Canada CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 24. Germany CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 25. France CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 26. U.K. CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 27. Italy CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 28. Russia CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 29. Nordic CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 30. Rest of Europe CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 31. Asia-Pacific CDK4/6 Inhibitors for Breast Cancer Market Share by Region (2016-2027) Figure 32. China CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 33. Japan CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 34. South Korea CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 35. Southeast Asia CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 36. India CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 37. Australia CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 38. Rest of Asia-Pacific CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 39. Latin America CDK4/6 Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 40. Mexico CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 41. Brazil CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 42. Rest of Latin America CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 43. Middle East & Africa CDK4/6 Inhibitors for Breast Cancer Market Share by Country (2016-2027) Figure 44. Turkey CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 45. Saudi Arabia CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 46. UAE CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 47. Rest of Middle East & Africa CDK4/6 Inhibitors for Breast Cancer Market Size (2016-2027) & (US$ Million) Figure 48. Bottom-up and Top-down Approaches for This Report Figure 49. Data Triangulation

Pfizer Beacon Pharmaceuticals Incepta Pharmaceuticals Pharmaceuticals Bluepharma NANO DARU Eli Lilly Novartis